Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001378538 | SCV001576125 | pathogenic | PRPH2-related disorder | 2023-07-07 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 209 of the PRPH2 protein (p.Val209Asp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with cone-rod dystrophy, macular dystrophy, and/or retinitis pigmentosa (PMID: 29555955, 34399712). ClinVar contains an entry for this variant (Variation ID: 1067308). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PRPH2 protein function. This variant disrupts the p.Val209 amino acid residue in PRPH2. Other variant(s) that disrupt this residue have been observed in individuals with PRPH2-related conditions (PMID: 20213611, 28041643), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
| Institute of Human Genetics, |
RCV004815505 | SCV005068602 | likely pathogenic | Retinal dystrophy | 2021-01-01 | criteria provided, single submitter | clinical testing | |
| Leiden Open Variation Database | RCV001530315 | SCV001745085 | pathogenic | not provided | 2021-02-14 | no assertion criteria provided | curation | Curator: Global Variome, with Curator vacancy. Submitter to LOVD: LOVD. |